上海神奇制药投资管理股份有限公司 2023 年度前期会计差错更正 专项说明的鉴证报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://sce.gnb.get.com.cn）"进行整 一 关于上海神奇制药投资管理股份有限公司 2023 年度前期会计差错更正专项说明的鉴证报告 信会师报字[2025]第 ZA15130 号 上海神奇制药投资管理股份有限公司全体股东: 我们接受委托,对后附的上海神奇制药投资管理股份有限公司 (以下简称"神奇制药公司") 2023 年度前期会计差错更正专项说明 (以下简称"专项说明")执行了合理保证的鉴证业务。 一、管理层的责任 神奇制药公司管理层的责任是按照《企业会计准则第 28 号 -- 会计政策、会计估计变更和差错更正》、中国证券监督管理委员会《公 开发行证券的公司信息披露编报规则第 19 号 -- 财务信息的更正及 相关披露》、《上海证券交易所股票上市规则》、《上海证券交易所上市 公司自律监管指南第2号 -- 业务办理》及《上海证券交易所上市公 司自律监管指南第1号 -- 公告格式》的相关规定编制专项说明,并 确保专项说明真实、准确、完整,不存在虚假记载 ...

上海神奇制药投资管理股份有限公司 2025 年第三季度报告 证券代码：600613 证券简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年第三季度报告 2025 年 10 月 1 / 14 上海神奇制药投资管理股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | ...

南财智讯10月30日电，神奇制药发布三季度报告，第三季度公司实现营业收入4.37亿元，同比下降 3.51%；归属于上市公司股东的净利润1749.35万元，同比下降18.70%。前三季度公司实现营业收入 13.98亿元，同比下降10.58%；前三季度归属于上市公司股东的净利润5030.16万元，同比下降15.25%。 ...

Core Viewpoint - The stock price of Shenqi Pharmaceutical has shown fluctuations, with a recent increase of 2.06% but a year-to-date decline of 4.17%, indicating potential volatility in the market [1][2]. Company Overview - Shenqi Pharmaceutical, established on July 22, 1992, and listed on August 20, 1992, is located at 128 Weihai Road, Shanghai. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The revenue composition of Shenqi Pharmaceutical includes: Other Specialty Products Series (43.60%), Antitumor Drug Series (25.86%), Traditional Chinese Medicine Cough Relief Series (12.09%), Chronic Disease Products Series (6.05%), Miao Medicine Strong Bone Series (4.58%), Skin Antibacterial Products (4.37%), Classic Nutritional Products Series (2.43%), and Shenqi Baby Medicine Series (1.00%) [2]. Financial Performance - For the first half of 2025, Shenqi Pharmaceutical reported a revenue of 961 million yuan, a year-on-year decrease of 13.47%, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% year-on-year [2]. - The company has distributed a total of 366 million yuan in dividends since its A-share listing, with 187 million yuan distributed over the past three years [3]. Market Activity - As of October 21, the stock price was 6.43 yuan per share, with a market capitalization of 3.434 billion yuan. The trading volume was 21.9066 million yuan, with a turnover rate of 0.72% [1]. - The net outflow of main funds was 550,800 yuan, with large orders buying 1.0123 million yuan (4.62%) and selling 1.5631 million yuan (7.14%) [1].

Group 1 - The company Shenzhou Pharmaceutical has received an administrative regulatory measure from the Shanghai Securities Regulatory Bureau due to financial misconduct involving the misappropriation of sales expenses amounting to 44.838 million yuan in 2023 [1] - The regulatory measures include a "rectification order" and warning letters issued to the company's chairman and two other executives, indicating serious issues with financial reporting and potential violations of the Securities Law [1] - The company claims that the regulatory actions stem from "non-standard accounting treatment of receivables" and asserts that it will actively rectify the situation without affecting normal operations, although market and legal perspectives are skeptical [1] Group 2 - In 2023, the company returned to profit growth under the leadership of Chairman Zhang Taotao, who took over from his father, but overall performance has been declining with revenue dropping since the peak in 2022 [2] - The company's main business segments are pharmaceutical manufacturing and commercial operations, with a revenue split of approximately 60% to 40%, relying heavily on older products that are facing challenges due to policy changes [2] - For the first half of 2025, the company reported revenue of 961 million yuan and a net profit of 32.808 million yuan, both showing declines of approximately 13.47% and 13.29% year-on-year, indicating ongoing struggles [2]

Core Viewpoint - Shanghai Magical Pharmaceutical Co., Ltd. has been found to have violated information disclosure regulations, leading to administrative regulatory measures from the China Securities Regulatory Commission (CSRC) [1] Summary by Sections Company Violations - In 2023, the company misappropriated sales expenses amounting to 44,838,280 yuan through a halted "basic drug promotion plan" and created fictitious accounts receivable, which had already been fully impaired [1] - This led to incorrect information being disclosed in the company's 2023 annual report, violating Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" [1] Regulatory Actions - The CSRC's Shanghai Bureau has mandated corrective actions for the company and issued warning letters to individuals including Zhang Tao Tao, Feng Bin, and Chen Zhimian [1] Legal Implications for Investors - Investors who suffered losses due to the company's violations can seek civil compensation, which includes investment differences, commissions, and stamp duties [2] - A lawyer is actively recruiting affected investors for litigation against the company, specifically targeting those who purchased shares between April 29, 2024, and September 26, 2025 [2] Litigation Process - While investors can file lawsuits without prior administrative penalties, the lack of thorough investigation may increase the risk of losing the case [3] - The status of the company, including potential delisting or bankruptcy, may affect the litigation process but does not halt it [3] Required Documentation for Claims - Investors must provide specific documents for compensation claims, including a copy of their ID, securities account information, and transaction records [3]

Policy Developments - The Ministry of Industry and Information Technology, along with two other departments, announced the initiation of the 2025 high-end medical equipment promotion application project [1] Drug and Device Approvals - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, aimed at treating cancer pain in adults, with no similar drugs currently on the market [2] - Heng Rui Medicine's subsidiary received approval for clinical trials of HRS-2129, targeting diabetic peripheral neuropathic pain and osteoarthritis pain, with a total R&D investment of approximately 112 million yuan [3] - Borui Pharmaceutical obtained FDA approval for the clinical trial of BGM1812 injection for overweight or obesity treatment, with no similar products approved globally [4] Capital Market - Hangzhou Yaojiasu Medical Isotope Technology Co., Ltd. announced the completion of several million yuan in angel round financing, aimed at expanding its core team and advancing technology development [5] Industry Events - The National Medical Insurance Administration has identified and addressed multiple cases of abnormal data, enhancing the regulatory capabilities of medical insurance data [7] - Xiangyu Medical signed a cooperation agreement with Zhejiang Provincial People's Hospital to establish a clinical research ward for brain-machine interfaces [8] - A micro "lung chip" with an embedded immune system was developed by researchers from Georgia Tech and Vanderbilt University, potentially revolutionizing disease research [9] Public Opinion Alerts - Shenqi Pharmaceutical faced a significant stock drop after being ordered to rectify issues related to the misappropriation of 44.83 million yuan in sales fees, leading to regulatory actions [10]

证券代码：A股 600613 股票简称：A股 神奇制药 编号：2025-033 ● 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公司"） 的股东贵州迈吉斯投资管理有限 公司（以下简称"迈吉斯"）持有公司88,001,946股，占公司总股本16.48%；本次质押45,280,000股，累计 质押股份76,650,000股，占公司总股份数14.35%，占其持有公司股份87.10%。 ● 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"）及其控股公司迈吉斯合计持有 公司178,663,566股，占公司总股本33.45%；累计质押股份121,980,000股，占公司总股份数22.84%，占 其合计持有公司股份68.27%。 2025年9月29日，公司接到迈吉斯关于股份质押的通知，迈吉斯向厦门国际银行股份有限公司厦门分行 （以下简称"厦门国际银行"）办理了股票质押业务，质押其持有的本公司无限售流通股45,280,000股， 占公司总股份数8.48%，占其持有公司股份51.45%。具体情况如下： 3、控股股东及其控股公司累计质押股份情况 截至公告披露日，神奇控股及迈吉斯累计质押股份情况如下： B ...

Core Viewpoint - The company Shenqi Pharmaceutical has faced regulatory scrutiny due to financial misconduct, leading to a significant drop in its stock price and raising concerns about its future performance [2][3]. Group 1: Regulatory Issues - Shenqi Pharmaceutical received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau, citing violations related to the misappropriation of sales expenses amounting to 44.838 million yuan through fictitious accounts [2]. - The company has been ordered to rectify its accounting practices, and three executives, including the chairman, received warning letters [2]. - The company claims that the regulatory measures will not affect its normal operations and is currently preparing a rectification report [2]. Group 2: Financial Performance - The company reported a net profit of less than 100 million yuan in recent years, a decline from levels seen before 2019, with revenue continuously decreasing since its peak in 2022 [3][6]. - For the first half of 2025, the company is projected to have revenues of 961 million yuan and a net profit of 32.808 million yuan, representing year-on-year declines of 13.47% and 13.29%, respectively [10]. - The main business segments of the company are pharmaceutical manufacturing and commercial operations, contributing approximately 60% and 40% to revenue, respectively [6]. Group 3: Market Challenges - The company's product line includes older medications, which have faced declining sales due to various healthcare cost control policies, such as payment reforms and price adjustments [6]. - Specific products, such as the sodium cantharidate injections, have seen significant sales in the past but are now categorized closer to auxiliary medications, impacting overall revenue [6].

Core Viewpoint - The company, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., has received administrative regulatory measures from the Shanghai Securities Regulatory Bureau due to irregularities in its accounting practices, specifically related to the handling of accounts receivable [1][2]. Group 1: Regulatory Actions - The Shanghai Securities Regulatory Bureau has mandated corrective measures for the company and issued warning letters to key executives, including the chairman and general manager, for their lack of diligence [1]. - The company is required to submit a written rectification report within 30 days and is expected to improve its accounting practices to prevent future occurrences [2]. Group 2: Financial Impact - In the first half of 2025, the company reported a revenue of 961 million yuan, a decrease of 13.47% year-on-year, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% year-on-year [2]. Group 3: Company Background - Shanghai Shenqi Pharmaceutical was listed on August 20, 1992, and its main business includes the research, production, and sales of pharmaceuticals, with key products being sodium cantharidate vitamin B6 injection and sodium cantharidate injection [2].